Journal
EMERGING INFECTIOUS DISEASES
Volume 28, Issue 3, Pages 548-555Publisher
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2803.212299
Keywords
-
Categories
Funding
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [20/05367-3]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [20/05367-3] Funding Source: FAPESP
Ask authors/readers for more resources
A multicenter randomized trial in Brazil showed that high-dose convalescent plasma transfusion within 10 days of symptom onset did not benefit patients with severe COVID-19.
To assess whether high-dose coronavirus disease (COVID-19) convalescent plasma (CCP) transfusion may benefit patients with severe COVID-19, we conducted a multicenter randomized trial in Brazil. Patients with severe COVID- 19 who were within 10 days of initial symptom onset were eligible. Patients in the CCP group received 3 daily doses of CCP (600 mL/d) in addition to standard treatment; control patients received standard treatment only. Primary outcomes were death rates at days 30 and 60 of study randomization. Secondary outcomes were ventilator-free days and hospital-free days. We enrolled 107 patients: 36 CCP and 71 control. At day 30, death rates were 22% for CCP and 25% for the control group; at day 60, rates were 31% for CCP and 35% for control. Needs for invasive mechanical ventilation and durations of hospital stay were similar between groups. We conclude that high-dose CCP transfused within 10 days of symptom onset provided no benefit for patients with severe COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available